Stay updated on Pembrolizumab for Advanced Merkel Cell Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Advanced Merkel Cell Cancer Clinical Trial page.

Latest updates to the Pembrolizumab for Advanced Merkel Cell Cancer Clinical Trial page
- CheckyesterdayChange DetectedNo significant changes detected on the page; the NCT02267603 study details for Pembrolizumab in Merkel cell carcinoma remain as published, including the overview and eligibility criteria.SummaryDifference0.3%

- Check9 days agoNo Change Detected
- Check30 days agoChange DetectedUpdate to version v3.2.0 and removal of a specific resource (Cutaneous neuroendocrine carcinoma); addition of an important government-operating status notice and links.SummaryDifference2%

- Check37 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no substantive content changes.SummaryDifference0.0%

- Check51 days agoChange DetectedVersion bumped to v3.0.2 and the Back to Top element removed. No significant core content changes.SummaryDifference0.1%

- Check59 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%

- Check66 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as the introduction of cutaneous neuroendocrine carcinoma and pembrolizumab. Notably, previous terms related to neuroendocrine tumors and various classifications of antineoplastic agents have been removed.SummaryDifference2%

Stay in the know with updates to Pembrolizumab for Advanced Merkel Cell Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Advanced Merkel Cell Cancer Clinical Trial page.